Photocure is a commercial-stage Norwegian speciality pharmaceutical company that currently markets Hexvix/Cysview, an imaging agent for diagnosing and managing bladder cancer. The franchise is currently profitable and growing at a 38% annual rate. The company is Phase III-ready for Cevira, a treatment for HPV-related diseases of the cervix. Finally, it is Phase III-ready for Visonac, potentially the first photodynamic treatment for moderate to severe inflammatory acne and addressing a large u
06 Aug 2015
Helping to detect and fight cancer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Helping to detect and fight cancer
Photocure is a commercial-stage Norwegian speciality pharmaceutical company that currently markets Hexvix/Cysview, an imaging agent for diagnosing and managing bladder cancer. The franchise is currently profitable and growing at a 38% annual rate. The company is Phase III-ready for Cevira, a treatment for HPV-related diseases of the cervix. Finally, it is Phase III-ready for Visonac, potentially the first photodynamic treatment for moderate to severe inflammatory acne and addressing a large u